Finerenone cuts CV and kidney risk

Finerenone is a kidney-and-heart protection drug for people with type 2 diabetes and chronic kidney disease. That group stays high-risk even when blood sugar, blood pressure, and cholesterol look pretty good on paper. The gap has been whether another drug still adds value after patients have already checked some of the usual treatment boxes. This new analysis says yes — finerenone kept lowering cardiovascular and kidney risk no matter how many American Diabetes Association treatment goals patients had already met at baseline. ### What exactly was analyzed? This was not a brand-new randomized trial. It was a FIDELITY analysis — basically a pooled look at two big phase 3 finerenone trials, FIDELIO-DKD and FIGARO-DKD, in people with type 2 diabetes plus chronic kidney disease. The researchers sorted patients by how many ADA-style treatment goals they had already achieved at study entry: HbA1c at or below 7.0%, blood pressure below 130/80 mmHg, LDL cholesterol below 1.81 mmol/L, and use of an SGLT2 inhibitor or GLP-1 receptor agonist. (nutrition-evidence.com) ### What did the groups look like? Most patients were not walking in with everything optimized. At baseline, 29% had met none of those goals, 40% had met one, 24% had met two, and only 7% had met three or more. That matters because it shows how hard “fully optimized care” still is in the real world, even inside major clinical trials. (nutrition-evidence.com) ### Did better baseline control matter? Yes — but in the way you would expect. In the placebo arm, people who had more goals under control had fewer cardiovascular events. The event rates for the composite cardiovascular outcome were 6.0, 5.1, 4.3, and 3.5 per 100 patient-years as baseline goal attainment rose from 0 to 1, 2, and 3 or more goals. So the standard targets still matter. Hitting them lowered background risk. (nutrition-evidence.com) ### So where does finerenone come in? Finerenone helped on top of that. The key point in the paper is that there was no heterogeneity in treatment effect across those baseline-goal subgroups. In plain English — the drug’s benefit did not disappear in people who were already doing more things right. The same pattern held across cardiovascular and kidney outcomes, plus heart-failure hospitalization measures. (nutrition-evidence.com) ### Why is that useful clinically? Because diabetes kidney care is moving toward combination therapy. Doctors already lean on ACE inhibitors or ARBs, and now often add SGLT2 inhibitors and sometimes GLP-1 drugs. The obvious question is whether finerenone becomes less useful once those layers are in place. This analysis pushes the answer toward no. It makes finerenone look additive — another protective layer, not just a substitute for poor baseline management. (nutrition-evidence.com) ### What kind of drug is finerenone? It is a nonsteroidal mineralocorticoid receptor antagonist. Basically, it blocks a pathway tied to inflammation and fibrosis in the kidney and cardiovascular system. In the U.S., finerenone is already approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal heart attack, and hospitalization for heart failure in adults with CKD associated with type 2 diabetes. (nutrition-evidence.com) ### Is there a catch? The usual one is potassium. Finerenone’s safety profile in this subgroup analysis was similar across baseline-goal groups, but the drug’s label still carries a hyperkalemia warning, so monitoring matters. This is not a “replace everything else” drug. It is an add-on therapy for the right patients, with labs and follow-up. (accessdata.fda.gov) ### Bottom line The new result is less about proving finerenone works — that was already known — and more about showing where it fits. Turns out it still helps even when patients have already hit some of the usual diabetes and kidney targets. That is a practical finding, because the future of CKD care in type 2 diabetes is layered treatment, not one magic pill. (nutrition-evidence.com)